Philipp Leidig

We support and invest in early-stage companies that disrupt the established ways how we generate, manage, and use energy. We believe that we must find new ways how to create connectivity between the physical and digital world in order to build the 21st century infrastructure to support how we live, move and work.

cylib GmbH is a research-based company for holistic battery recycling enabling the green energy transition by ensuring the supply of sustainable raw materials for the battery industry. cylibs proprietary end-to-end recycling process is characterized by an efficient, resource- and climate-friendly recovery of all raw materials in a battery, including lithium, graphite, nickel, cobalt and manganese from battery packs, production scraps, or micromobility batteries. Founded in 2022 in Aachen, Germany, the company builds on nearly a decade of research by the founding team. cylib was founded by Dr. Lilian Schwich (Co-CEO), Paul Sabarny (Chief of Special Operations), and Dr. Gideon Schwich (Co-CEO), with the mission to create a true circular economy.

Prothea Technologies is a private medical technology company with a vision to offer lung cancer biopsy and treatment in a single hospital visit. Lung cancer is the third most common form of cancer in the U.S. and annually claims more lives than breast, prostate and colon cancer combined.

Improving critical care management

EINHUNDERT gives real estate companies the opportunity to think tenant power big: Thanks to innovative software and standardized processes, a cost-efficient tenant power rollout is made possible across the entire building portfolio. In addition, EINHUNDERT manages service processes related to energy generation and digital metering point operation.

We help to decarbonise the global economy. As a climate tech VC, we are driven by tackling the climate crisis and only invest in technologies with scalable businesses and significant emissions savings potential. We support startups from early to growth stage, focusing on Energy, Food and Agriculture, Manufacturing, Buildings, and Mobility. Entrepreneurs who understand decarbonisation as a value driver are whom we back; those who think big, act macro; those who build tech for a regenerative world.

ECBF is a growth-stage venture capital fund established in Luxembourg dedicated to growth-stage investments within the European Circular Bioeconomy. We bring Europes circular technologies to market, identifying the most promising investment targets, and syndicating with private and public investors to join financial rounds. Our mission is to provide access to finance to innovative solutions that enable the transitioning from a linear economy to a more sustainable circular one, having the European Investment Bank as a cornerstone investor. Our targeted investment sectors include new technologies and business models in Agtech; blue economy; and bio-based chemicals, specialities and materials; with applications on Nutrition; packaging, personal care, construction, and textiles. Investment opportunities in circularity -i.e., conversion of biological resources and waste streams into value-added products- have a high priority. We believe that investing now in circular businesses and technologies will be beneficial to both a growing market segment and a cleaner future.

Die Deutsche Arzt Management GmbH (DAMG) ist ein junges und innovatives Unternehmen, gegründet von Ärzten, Leistungserbringern und Unternehmern. Die DAMG verfolgt das Ziel, kompetente Gesundheitsleistungen für Patienten und Konsumenten schneller und besser verfügbar zu machen. Mit den neuen Möglichkeiten die das Internet und die digitale Welt bietet, verbindet das Unternehmen Patienten, Konsumenten, professionelle Gesundheitsanbieter, Krankenkassen und Unternehmen, die sich um die Gesundheit ihrer Mitarbeiter kümmern. Die konzeptionelle Entwicklung sowie der Aufbau der DAAG Dienstleistungen begann bereits im Jahr 2013 aus der Struktur der NOVOTERGUM Gruppe. Ende 2015 wurde dann die Deutsche Arzt AG als eigenständige Aktiengesellschaft gegründet. Am 01.03.2022 überträgt die Deutsche Arzt AG im Rahmen der Transaktion ihren Geschäftsbetrieb auf die Deutsche Arzt Management GmbH, einer Tochtergesellschaft der UNITED THERAPY. Neben wertschöpfenden Dienstleistungen für Ärzte wie zum Beispiel individuelle Websites, Marketingunterstützung und Schulungsangeboten zählen innovative Leistungsangebote aus dem Bereich Digital Health und Versorgungsverträge mit Krankenkassen zu den DAMG Kernleistungen. Die Deutsche Arzt Management GmbH vernetzt als erster Leistungsanbieter in Deutschland online-Therapie mit online-Sprechstunde und digitalen Leistungen für das betriebliche Gesundheitsmanagement und bindet diese Leistungen in innovative Versorgungsverträge mit Krankenkassen ein. Impressum Postanschrift: Deutsche Arzt Management GmbH Im Teelbruch 118 45219 Essen Deutschland Telefon: 02054 93856-0 Telefax: 02054 93856-1 Mail: info@daag.de Sitz der Gesellschaft: Essen Amtsgericht: Essen, HRB 32596 Geschäftsführung: Jochen Roeser (Vorsitzender), Stephan Kretschmer

UBIRCH is a digital data proof solution that brings security into data driven processes and establishes trust between multiple stakeholders. It’s one cloud-based Proof Machine that enables everyone involved to verify the authenticity and integrity of data received. Founded and managed by experienced specialists in cryptography, blockchain and data-driven business models, UBIRCH is combining robust cryptography and modern blockchain technology into an innovative, easy to use SaaS product. Together with a consortium of renowned companies, the Cologne-based company has developed and is operating the official infrastructure of the EU Digital COVID Certificate for Germany. Further information is available at www.ubirch.com

Digitization often starts by interfacing to the real world with sensors and smart devices. Providing billions of devices with electrical energy is one of the big challenges of a growing internet of things. The need for frequent replacement of batteries or labour- and cost-intensive wiring is not only a significant cost factor. The constraints in energy supply can also be a show-stopper for implementing new solutions. As a result, a large potential of the internet of things remains untapped. Light is often an abundant source of energy – not only outdoors, but also indoors. Enerthing has developed the next generation photovoltaic film which can outperform batteries. Based on our core technology, we bring asset-tracking, indoor navigation and sensing in buildings to the next level combining high performance, maintenance-free operation and sustainability. With our broad expertise ranging from manufacturing of high performance customizable photovoltaic films, energy efficient hardware and software systems design we develop new IoT solutions which push the boundaries of today’s battery powered and cable tied IoT world.

We support and invest in early-stage companies that disrupt the established ways how we generate, manage, and use energy. We believe that we must find new ways how to create connectivity between the physical and digital world in order to build the 21st century infrastructure to support how we live, move and work.

cylib GmbH is a research-based company for holistic battery recycling enabling the green energy transition by ensuring the supply of sustainable raw materials for the battery industry. cylibs proprietary end-to-end recycling process is characterized by an efficient, resource- and climate-friendly recovery of all raw materials in a battery, including lithium, graphite, nickel, cobalt and manganese from battery packs, production scraps, or micromobility batteries. Founded in 2022 in Aachen, Germany, the company builds on nearly a decade of research by the founding team. cylib was founded by Dr. Lilian Schwich (Co-CEO), Paul Sabarny (Chief of Special Operations), and Dr. Gideon Schwich (Co-CEO), with the mission to create a true circular economy.

Prothea Technologies is a private medical technology company with a vision to offer lung cancer biopsy and treatment in a single hospital visit. Lung cancer is the third most common form of cancer in the U.S. and annually claims more lives than breast, prostate and colon cancer combined.

Algiax Pharmaceuticals GmbH is an independent biotechnology company that was established in April 2011. It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need. In the field of nervous system disease, Algiax has a strong focus on neuropathic pain and acute spinal cord injury. Algiax’ lead candidate AP-325 is in clinical development for the treatment of neuropathic pain. A selection of new chemical entities (AP-4 & AP-8) is in preclinical development for the treatment of Diabetes Type 1. Algiax’ strategy is to develop its drug candidates up to a Clinical Phase II-III stage and out-license them to pharmaceutical and biotech companies for further clinical development and market authorisation.

Improving critical care management